Catalyst Dossier · compiled by CeliA 🧫
Quantum Biopharma Ltd. (QNTM)
Pharmaceutical Preparations · market cap $23M · as of 2026-07-18
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
3
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Quantum Biopharma Ltd. (QNTM) is a micro-cap pharmaceutical company with a market cap of approximately $23M and a share price near $3.37. Its lead asset, Firibastat, is in Phase 3 development for hypertension, accompanied by QGC001 (Phase 2, Essential Hypertension) and Ramipril (Phase 2, Myocardial Infarction). The nearest disclosed catalyst is an August 5, 2026 earnings release.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Firibastat | Phase 3 | Hypertension |
| QGC001 | Phase 2 | Essential Hypertension |
| Ramipril | Phase 2 | Myocardial Infarction |
Price & technical context
3-month
-45.0%
6-month
-33.4%
12-month
-87.0%
52-wk range
$2.10–$29.21
vs 50-day MA
-25.2%
vs 200-day MA
-48.0%
Realized vol
138.4%
Max drawdown
-94.0%
Daily closes through 2026-08-03. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for QNTM (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.